Computed Tomography Manifestations and Excision Cross-Complementation Group 1 Expression of Stage I Non–Small-Cell Lung Cancer and Their Correlation With Prognosis

Objective: The aim of this study was to evaluate the computed tomography (CT) manifestations and expression of the excision cross-complementation group 1 (ERCC1) and their correlation with prognosis in stage I non–small-cell lung cancer (NSCLC). Materials and Methods: A total of 133 patients with stage I NSCLC with complete 3- and 5-year disease-free survival (DFS) and overall survival (OS) data, who underwent thoracic CT and pathological examination, were included. Expression of ERCC1 in tumor samples was evaluated using semiquantitative immunohistochemical analysis. Results: The 3- and 5-year DFS rates for the 133 patients were 72.2% and 60.9%, respectively, and the 3- and 5-year OS rates were 89.5% and 82.0%, respectively. Significant differences in the 3- and 5-year DFS occurred (P = 0.003 and P = 0.001, respectively), whereas no significant differences in the 3- and 5-year OS were found (P = 0.099 and P = 0.062, respectively) between high and low ERCC1 protein expression. Patients with high expression of ERCC1 had a better prognosis. There was a significant correlation between tumors with an irregular edge and signs of spiculation on CT and low expression of ERCC1 evaluated using logistic regression analysis (P

http://ift.tt/29Uqpsj